e-learning
resources
Virtual 2020
Pre-Congress Content
Inhaled corticosteroids and bronchodilator studies in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Adherence to FDC Budesonide/Formoterol treatment and lung function of Greek asthmatic patients–COMPLETE study
N. Rovina (Attica, Greece), D. Simantiraki (Attica, Greece), N. Grekas (Attica, Greece), P. Papanastasiou (Attica, Greece), A. Athanassiou (Attica, Greece), A. Ginis (Attica, Greece)
Source:
Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Session:
Inhaled corticosteroids and bronchodilator studies in asthma
Session type:
E-poster session
Number:
2635
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Rovina (Attica, Greece), D. Simantiraki (Attica, Greece), N. Grekas (Attica, Greece), P. Papanastasiou (Attica, Greece), A. Athanassiou (Attica, Greece), A. Ginis (Attica, Greece). Adherence to FDC Budesonide/Formoterol treatment and lung function of Greek asthmatic patients–COMPLETE study. 2635
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Respiratory sequelae of preterm birth across the life span
Time to breathe: Challenges in the successful management of asthma during conception, pregnancy and delivery
Related content which might interest you:
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Lung function and reported dyspnea in Greek COPD patients under treatment with fluticasone/salmeterol FDC via Elpenhaler device with or without cardiovascular comorbidity - AEOLOS study.
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021
Efficacy of the using budesonide/formoterol in patients with bronchial asthma (BA): the study of routine clinical practice
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006
Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Lung function and symptom improvement with fluticasone/salmeterol and ipratropium/albuterol in albuterol responsive and non-responsive COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 89s
Year: 2004
Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies.
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020
QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta
2
-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
Effects of add-on treatment with budesonide/formoterol combination in eosinophilic COPD patients
Source: International Congress 2017 – Management of COPD
Year: 2017
Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
Predictive factors for asthma control according to ACQ
5
in asthma patients treated with budesonide/formoterol maintenance and reliever therapy. Results from the EuroSMART study
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010
Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
A new budesonide/formoterol inhalation therapy in patients with asthma, COPD and ACOS
Source: International Congress 2017 – Bronchial asthma management
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept